AQST NASDAQ
Aquestive Therapeutics, Inc.
1W: +0.5%
1M: -14.3%
3M: +13.1%
YTD: -36.9%
1Y: -40.5%
3Y: +164.3%
5Y: -4.0%
$4.07
+0.10 (+2.52%)
Weekly Expected Move ±8.5%
$3
$4
$4
$4
$5
Credit Risk of going bust: higher than 66% of companies Debt: 10.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 98%), Aquestive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $59.0M against a stock market value of $510.8M.
Distance to default 3.71 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $25.3M (short-term plus half of long-term), stock volatility 79.2%; Altman Z -3.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 98%), Aquestive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $59.0M against a stock market value of $510.8M.
Distance to default 3.71 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $25.3M (short-term plus half of long-term), stock volatility 79.2%; Altman Z -3.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-03-26
Earliest Filing
2026-03-04
Latest Filing
partner: 13
investor: 3
licensee: 1
Counterparties (Filed by AQST)
17 relationshipsCompanies named in AQST's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| RTW Investments, LP | — | investor | Investor entering into amendment to purchase agreement and warrant issuance agreement. | 2026-03-04 | View |
| Leerink Partners LLC | — | partner | Underwriter for the underwritten offering of common stock | 2025-08-15 | View |
| Cantor Fitzgerald & Co. | — | partner | Underwriter for the underwritten offering of common stock | 2025-08-15 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Underwriter for the underwritten offering of common stock | 2025-08-15 | View |
| RTW Investments LP | — | investor | Purchaser of assigned interests in Anaphylm for $75 million with tiered revenue share payments. | 2025-08-14 | View |
| Leerink Partners LLC | — | partner | Served as representative underwriter for the public offering of common stock | 2024-03-21 | View |
| Piper Sandler & Co. | PIPR | partner | Served as representative underwriter for the public offering of common stock | 2024-03-21 | View |
| Indivior Inc. | INDV | partner | Amendment to Commercial Exploitation Agreement extending term and adjusting pricing terms | 2023-03-06 | View |
| Otter Pharmaceuticals, LLC | — | licensee | Licensee of Sympazan oral film for the treatment of seizures associated with Lennox-Gastaut syndrome | 2022-10-27 | View |
| Assertio Holdings, Inc. | ASRT | partner | Parent company of Otter Pharmaceuticals, LLC | 2022-10-27 | View |
| A.G.P./Alliance Global Partners | — | partner | Placement agent for the registered direct offering | 2022-06-08 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Entered into a purchase agreement and registration rights agreement to acquire up to $40,000,000 of common stock. | 2022-04-13 | View |
| Haisco Pharmaceutical Group Co., Ltd. | — | partner | Entered into a licensing and supply agreement for EXSERVAN (riluzole oral film) for ALS treatment in China. | 2022-03-03 | View |
| Zambon S.p.A. | — | partner | Mentioned as a licensee for EXSERVAN in Europe. | 2022-03-03 | View |
| Mitsubishi Tanabe Pharma America | — | partner | Mentioned as a licensee for EXSERVAN in the United States. | 2022-03-03 | View |
| Sunovion Pharmaceuticals Inc. | — | partner | Third Amendment to License Agreement clarifying field definition and sublicensee rights. | 2021-07-30 | View |
| Piper Sandler & Co. | PIPR | partner | Entered into an amended Equity Distribution Agreement to facilitate the sale of common stock. | 2021-03-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-19 | Bylaws Amendment; Exhibits | View | |
| 2026-10-15 | Regulation FD; Exhibits | View | |
| 2026-10-14 | Material Agreement; Exhibits | Agreement | View |
| 2026-09-29 | Officer/Director Change; Exhibits | View | |
| 2026-09-25 | Regulation FD; Exhibits | View | |
| 2026-09-17 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-11 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-08-10 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-10 | Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Material Agreement; Termination of Agreement; Earnings Release; Financial Obligation; Unregistered E | Agreement | View |
| 2026-03-30 | Regulation FD; Exhibits | View | |
| 2026-03-20 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-04 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Unregistere | Agreement | View |
| 2026-02-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-01 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR